Xu Jing-Hang, Yu Yan-Yan, Si Chong-Wen, Zeng Zheng, Wang Qin-Huan, Luo Duan-De, Zhou Yong-Xing, Zeng Min-De, Qiao Guang-Yan, Yao Ji-Lu, Lu Wei-Lun
Department of Infectious Diseases, First Hospital of Beijing University, Beijing 100034, China.
Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):381-5.
The mortality rate of heavy type hepatitis is high. No special treatment is available except general treatment. This multicenter clinical study was designed to observe the safety and efficacy of promoting hepatic growth factor (PHGF) in the treatment of heavy type hepatitis and severe chronic hepatitis.
347 patients with heavy type hepatitis and 324 with severe chronic hepatitis were subjected to administration of 120 microg of PHGF per day for 4 weeks on the basis of general treatment. Those who were being effectively treated would last additional 2 to 4 weeks. Blood routine, urine routine, blood urea nitrogen (BUN), blood creatinine (Cr), blood ammonia, alpha fetoprotein (AFP), electrolyte, alanine transaminase (ALT), aspartate transaminase (AST), serum total bilirubin (TBIL), serum direct bilirubin (DBIL), prothrombin time activity (PTA), total protein (TP) and albumin (ALB) were detected in the patients before treatment, 2 weeks after treatment, and at the end of the treatment. Any side-effect would be recorded.
In the patients with severe chronic hepatitis, the total effective rate of the treatment was 88.9%. The levels of ALT, AST and TBIL decreased significantly (P<0.001), whereas those of PTA and ALB increased significantly (P<0.001), and the level of AFP increased slightly. In patients with heavy type hepatitis, the total effective rate of this treatment was 78.4%, and patients at different stage showed different results. The total effective rates of patients with early, medium and terminal stage heavy type hepatitis were 89.9%, 84.8% and 27.5%, respectively. No severe side-effect was shown.
PHGF is effective and safe in the treatment of patients with heavy type hepatitis and severe chronic hepatitis. But it should be administered early in patients with heavy type hepatitis so as to get better curative effects.
重型肝炎病死率高，除一般治疗外尚无特效治疗方法。本多中心临床研究旨在观察促肝细胞生长素（PHGF）治疗重型肝炎和重度慢性肝炎的安全性及疗效。
347例重型肝炎患者和324例重度慢性肝炎患者在一般治疗基础上，每天给予120μg PHGF，疗程4周。有效者继续用药2至4周。于治疗前、治疗2周后及疗程结束时检测患者血常规、尿常规、血尿素氮（BUN）、血肌酐（Cr）、血氨、甲胎蛋白（AFP）、电解质、谷丙转氨酶（ALT）、谷草转氨酶（AST）、血清总胆红素（TBIL）、血清直接胆红素（DBIL）、凝血酶原时间活动度（PTA）、总蛋白（TP）及白蛋白（ALB），记录不良反应。
重度慢性肝炎患者治疗总有效率为88.9%。ALT、AST及TBIL水平显著下降（P<0.001），PTA及ALB水平显著升高（P<0.001），AFP水平略有升高。重型肝炎患者治疗总有效率为78.4%，不同病期疗效不同，早期、中期及晚期重型肝炎患者总有效率分别为89.9%、84.8%及27.5%。未出现严重不良反应。
PHGF治疗重型肝炎和重度慢性肝炎安全有效，但重型肝炎患者应早期用药，以提高疗效。
